FRANKREICH

Samba Digital, Inc: Samba Digital strengthens its iGaming services with new affiliate marketing services and expands into Africa

Retrieved on: 
Vendredi, mai 3, 2024
Marketing, Acquisition, Growth

Lisbon (Portugal) - April 22, 2024 – 18:00 PM CET: Samba Digital (ISIN PTDGL0AM0003 Mnemonic MLSMB), a global player in sports marketing, continues its growth by introducing affiliate marketing solutions and expanding its geographical presence, notably in Africa, to meet the increasing demand from iGaming operators.

Key Points: 
  • Lisbon (Portugal) - April 22, 2024 – 18:00 PM CET: Samba Digital (ISIN PTDGL0AM0003 Mnemonic MLSMB), a global player in sports marketing, continues its growth by introducing affiliate marketing solutions and expanding its geographical presence, notably in Africa, to meet the increasing demand from iGaming operators.
  • Affiliate marketing is a business model where iGaming companies, called "operators," collaborate with external partners, known as "affiliates."
  • Camila Cunha, iGaming Manager at Samba Digital, explains: "Our goals for this year include enriching our offerings with affiliate marketing and broadening our global presence, particularly in Africa.
  • Catarina, with her valuable experience, will play a key role in achieving our iGaming ambitions."

2CRSi SA: 2CRSi opens up to a market of over 300 million CAD for energy reuse.

Retrieved on: 
Vendredi, mai 3, 2024
Communication, Electricity, Research, Carbon

2CRSi SA: 2CRSi opens up to a market of over 300 million CAD for energy reuse.

Key Points: 
  • 2CRSi SA: 2CRSi opens up to a market of over 300 million CAD for energy reuse.
  • 2CRSi opens up to a market of over 300 million CAD for energy reuse.
  • Since 2015, 2CRSi has been working to design innovative solutions for reusing the energy wasted as heat by computer servers.
  • Together with its local partner, 2CRSI has just opened up a new market worth over 300 million Canadian dollars in Quebec.

Kaufman & Broad SA: AVAILABILITY OF THE PREPARATORY DOCUMENTS FOR THE COMBINED ORDINARY AND EXTRAORDINARY GENERAL MEETING OF 2024, MAY 6TH

Retrieved on: 
Vendredi, mai 3, 2024
Combined, Mail

Kaufman & Broad SA: AVAILABILITY OF THE PREPARATORY DOCUMENTS FOR THE COMBINED ORDINARY AND EXTRAORDINARY GENERAL MEETING OF 2024, MAY 6TH

Key Points: 
  • Kaufman & Broad SA: AVAILABILITY OF THE PREPARATORY DOCUMENTS FOR THE COMBINED ORDINARY AND EXTRAORDINARY GENERAL MEETING OF 2024, MAY 6TH
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • The terms of participation and voting at this meeting are set out in these two notices.
  • The documents and preparatory information relating to this meeting are available to shareholders and can be consulted on the Company's website at www.kaufmanbroad.fr in the section “shareholders’ meeting”, in accordance with the applicable legal and regulatory provisions.

Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program

Retrieved on: 
Vendredi, mai 3, 2024
Euronext Growth, Ratio, ADS, Therapy, American depositary receipt, ADR, Effective date, Notifiable disease

The effective date of the Ratio Change (the “Effective Date”) is expected to be April 23, 2024.

Key Points: 
  • The effective date of the Ratio Change (the “Effective Date”) is expected to be April 23, 2024.
  • ADS beneficial holders who hold through an ADR holder intermediary need not take any action in connection with the Ratio Change.
  • No new Shares will be issued in connection with the Ratio Change and this Ratio Change does not change the total number of Biophytis ordinary shares.
  • As a result of the Ratio Change, the trading price of the Company’s ADSs is expected to automatically increase proportionally, but the Company can give no assurance that the ADS trading price following the Ratio Change will be at least equal to the ADS trading price before the Ratio Change multiplied by the new 40:1 ratio.

Biophytis Announces Transfer of ADSs to OTC Market

Retrieved on: 
Vendredi, mai 3, 2024
OTCQB, OTC, Security (finance), Therapy, OTC Markets Group

As a result of the Panel’s decision, Nasdaq will suspend trading in the Company’s ADSs effective with the opening of business on Friday, April 26, 2024, and file a Form 25 with the Securities and Exchange Commission (the “SEC”) to effect the formal delisting of the Company’s ADSs from The Nasdaq Capital Market once all applicable Nasdaq appeal and review periods have expired.

Key Points: 
  • As a result of the Panel’s decision, Nasdaq will suspend trading in the Company’s ADSs effective with the opening of business on Friday, April 26, 2024, and file a Form 25 with the Securities and Exchange Commission (the “SEC”) to effect the formal delisting of the Company’s ADSs from The Nasdaq Capital Market once all applicable Nasdaq appeal and review periods have expired.
  • The Company anticipates that, concurrent with the suspension of trading of its ADSs on Nasdaq, the Company’s ADSs will begin trading on the OTC Markets’ OTC Pink Current Information tier under the current symbol “BPTS” while it applies to trade on the higher-tier OTCQB market.
  • The Company expects that this transfer will meaningfully reduce its ongoing costs of being a publicly-traded company.
  • The Company’s ordinary shares remain listed on Euronext Growth Paris as the primary trading market and the Company intends to continue its public disclosures in compliance with applicable French financial market regulations.

Freelance.com: 2023 results; strong EBITDA growth (+9%)

Retrieved on: 
Vendredi, mai 3, 2024
Depreciation, TMC, Investment, Openwork, STA, Growth, Policy, Pharmaceutical industry

*EBITDA = EBITDA = Operating income before depreciation and amortization and operating provisions, primarily for liabilities and charges and post-employment benefits.

Key Points: 
  • *EBITDA = EBITDA = Operating income before depreciation and amortization and operating provisions, primarily for liabilities and charges and post-employment benefits.
  • Consolidated revenue for full-year 2023 amounted to €857.7m, up 7% from 2022 (+4% organic growth).
  • International economic uncertainty and the slowdown in hiring momentum have decelerated our customers' use of freelancers in 2023.
  • Freelance.com generated €29.4m EBITDA in 2023, up 9% year-on-year, from €27.0m in 2022.

Affluent Medical : 2023 financial results and update on clinical activities under development.

Retrieved on: 
Vendredi, mai 3, 2024
Medtech, FDA, Risk, De novo, Death, Mitral regurgitation, Doctor of Philosophy, Wound healing, Mitral valve annuloplasty, Boston Scientific, Ticker, Wealth, Urinary incontinence, Woman, Christophe, Food, Neurostimulation, Myocardial infarction, Aix-en-Provence, DSM-IV codes, LCEA, Mitral valve, TAVI, Minerva, Certification, Heart, Quality assurance, System, Anatomy, Exercise, NYHA, Dry, Marketing, Clinical trial, American College, Development director, MD, Endocarditis, Medtronic, Patient, Tricuspid valve, Acquisition, Medical device

Affluent Medical : 2023 financial results and update on clinical activities under development.

Key Points: 
  • Affluent Medical : 2023 financial results and update on clinical activities under development.
  • Affluent Medical estimates that KaliosTM would avoid repeat surgery for 30-40% of patients within five years of their operation.
  • In September 2023, the Company presented interim data on 20 patients treated in five clinical centers in Europe after one year of implantation.
  • In July 2023, Affluent Medical announced the appointments of Christophe de Vregille as Chief Financial Officer and Benjamin Renault as Development Director.

AMUNDI ETF – Important Information – Mergers on Amundi Funds – 25/04/2024

Retrieved on: 
Vendredi, mai 3, 2024
Microsoft Excel, ETF, Absorption, Overview, Security (finance)

They can also be found on Amundi website: Important information: Merger of several ETFs | Amundi ETF Luxembourg | Retail

Key Points: 
  • They can also be found on Amundi website: Important information: Merger of several ETFs | Amundi ETF Luxembourg | Retail
    The Absorbed ETFs below will merge into the Receiving ETFs on 25/04/2024.
  • The receiving tickers in green will be transferred and activated on the merger date, please find the details in the table below.
  • Tickers in green = new tickers, tickers in red = discontinued tickers.
  • Please refer to the Overview section of the Excel file attached for more information.

Valbiotis publishes its annual accounts 2023

Retrieved on: 
Vendredi, mai 3, 2024
FDA, Sales management, Partnership, Hypercholesterolemia, Sleep, INSIGHT, Prevalence, Insulin resistance, Inflammation, DSM-IV codes, Food, Communication, Cholecalciferol, Executive Committee, Pharmacist, Pharmacy, Volunteering, INAF, Phase, Practitioner, Incretin, EFSA, Safety, Omega-3 fatty acid, Agonal respiration, Human, LDL, Marketing, Prediabetes, NAFLD, Endocrine gland, NDI, Food and Drug Administration, Meal, Commercial, Dietary supplement, Blood pressure, Patient, Statutory auditor, Metabolism, Hypertension, Cardiovascular disease, Bank statement, Pharmaceutical industry

Sébastien PELTIER, Chairman of the Executive Committee and Co-Founder of Valbiotis, comments: ‘’2023 was one of Valbiotis' most productive years since the Company was founded just ten years ago.

Key Points: 
  • Sébastien PELTIER, Chairman of the Executive Committee and Co-Founder of Valbiotis, comments: ‘’2023 was one of Valbiotis' most productive years since the Company was founded just ten years ago.
  • By accelerating its structuring, Valbiotis also laid the foundations for 2024, which promises to be particularly fruitful.
  • The Company's 2023 financial statements, drawn up in accordance with IFRS, were approved by the Board of Directors on April 23, 2024.
  • They have been audited by the Statutory Auditor and are available on the Valbiotis website: www.valbiotis.com/en (investors section).